Showing results (1-10 of 356) with videos related to
Sort By:
Pageof 36
International Journal of Molecular Sciences|June 27, 2024
Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic TargetsRobin Reschke, Alexander H Enk, Jessica C HasselPharmaceutics|August 29, 2024
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous MelanomaRobin Reschke, Alexander H Enk, Jessica C HasselAmerican Journal of Clinical Dermatology|December 20, 2024
Prognostic Biomarkers in Evolving Melanoma ImmunotherapyRobin Reschke, Alexander H Enk, Jessica C HasselCells|October 15, 2024
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)Ahmed M Mousa, Alexander H Enk, Jessica C Hassel, et al.Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.Biomolecules|March 29, 2023
S100 as Serum Tumor Marker in Advanced Uveal MelanomaMartin Salzmann, Alexander H Enk, Jessica C HasselInternal Medicine (Tokyo, Japan)|January 8, 2013
Necrolytic migratory erythema in a patient with neuroendocrine carcinomaMichaela Gronau, Dirk Jäger, Alexander H Enk, et al.Journal of Cutaneous Pathology|January 15, 2016
Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinomaMarta Kogut, Ferdinand Toberer, Alexander H Enk, et al.Frontiers in Immunology|April 2, 2024
The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?Robin Reschke, Benjamin Deitert, Alex H Enk, et al.Cancer Immunology, Immunotherapy : CII|March 9, 2018
Rituximab as a therapeutic option for patients with advanced melanomaJulia K Winkler, Matthias Schiller, Carolin Bender, et al.Pageof 36